ASH 2023 | Dara-RVD, with an MRD-adaptive duration of therapy, in high-risk smoldering myeloma
Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a Phase II trial (NCT04775550) assessing a quadruplet regimen of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in patients with high-risk smoldering multiple myeloma (HR-SMM), with measurable residual disease (MRD)-adaptive duration of therapy. The safety profile of this treatment approach is favorable, and the overall response rate (ORR) is 100% to date, with high levels of MRD negativity. Dr Nadeem awaits long-term follow-up results to confirm these findings. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on an entity’s Board of Directors or advisory committees: BMS, Sanofi, GPCR Therapeutics, GSK, Takeda, Janssen; Research Funding: Takeda, Janssen; Honoraria: Janssen.
